Cardinal Health expands at-Home Solutions with two tuck-ins for $360M
Jul 20, 2026, 4:47 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Accretive earnings in 12 months, expanded addressable market in diabetes/urology, and a demonstrated integration track record with ADS support likely to lift fundamentals and investor sentiment.
AI summary
What happened, with direct paths to the underlying reporting
Cardinal Health announced two tuck-in acquisitions—AdaptHealth's Diabetes Health and Strive Medical—for about $360 million in cash, expanding its at-Home Solutions platform into diabetes and urology. The deals are expected to be accretive to non-GAAP EPS within 12 months and build on ADS integration progress, including onboarding roughly 500,000 new customers and the ContinuCare Pathway program, signaling stronger home-care scale.
Cardinal Health to acquire AdaptHealth Diabetes Health and Strive Medical for $360M.
Deals expand Cardinal's at-Home Solutions into diabetes and urology. EPS accretion expected in 12 months.
Deal subject to regulatory approvals. Accretion expected in the first year.
J.P. Morgan advised on both acquisitions; Skadden and BakerHostetler provided counsel.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Cardinal Health posted a mixed Q4, with revenue up 6% and profits helped by a one-time tariff refund. The company issued fiscal 2027 EPS guidance above consensus, driven by solid…
Cardinal Health has increased its profit forecast for 2026, citing strong demand for specialty and branded medicines in its pharmaceuticals division. This positive outlook indicat…
Cardinal Health reported strong fiscal second-quarter results, with a 19% revenue increase to $65.6 billion and an elevated non-GAAP EPS guidance of $10.15-$10.35 for FY 2026, fue…